Table 4.

Risk of bleeding in RCTs of extended VTE treatment with DOACs

	Dabigatran		Rivaroxaban			Apixaban
	RE-MEDY (versus VKA) [35]	RE-SONATE (versus placebo) [35]	EINSTEIN-EXT (versus placebo) [18]	EINSTEIN-CHOICE (versus ASA 100 mg) [36]		AMPLIFY-EXT (versus placebo) [37]
	150 mg	150 mg	20 mg	20 mg	10 mg	5 mg	2.5 mg
Recurrent VTE	=	↓	↓	↓	↓	↓	↓
MB or CRNM	↓	↑	↑	=	=	=	=
MB	=	–	–	=	=	=	=
GIB	–	–	–	–	–	–	–
ICH	–	–	–	–	–	–	–

ASA aspirin, CRNMB clinically relevant non-major bleeding, GIB gastrointestinal bleeding, ICH intracerebral hemorrhage, MB major bleeding, MGIB major gastrointestinal bleeding, NVAF non-valvular atrial fibrillation, SE systemic embolism, VKA vitamin k antagonist, VTE venous thromboembolism

Symbols: = similar; ↓ minor; ↑ higher [hazard ratio (HR) of events with DOACs versus warfarin]; – no data